Literature DB >> 7965786

Inhibition of the biotransformation and pharmacological actions of glyceryl trinitrate by the flavoprotein inhibitor, diphenyleneiodonium sulfate.

J J McGuire1, D J Anderson, B M Bennett.   

Abstract

Recent studies suggest a role for the vascular cytochrome P450-NADPH cytochrome P450 reductase system in mediating the biotransformation of glyceryl trinitrate (GTN) to nitric oxide (or some closely related species), resulting in increased cyclic GMP accumulation and vasodilation. In this study we tested the effect of the flavoprotein inhibitor, diphenyleneiodonium sulfate (DPI) on GTN action in isolated rat aorta. Exposure of phenylephrine-contracted tissues to DPI (10 nM-0.3 microM) resulted in 3- to 10-fold increases in the EC50 values for GTN-induced relaxation in both endothelium-intact tissues and endothelium-denuded tissues, whereas the vasodilator response to sodium nitroprusside was unaffected. Consistent with the relaxation data, cyclic GMP accumulation induced by 0.3 or 2 microM GTN was inhibited by 0.3 microM DPI in both endothelium-intact and endothelium-denuded aortic strips, whereas cyclic GMP accumulation induced by 0.1 microM sodium nitroprusside was unaffected. The regioselective formation of glyceryl-1,2-dinitrate observed during the aortic biotransformation of GTN was inhibited markedly by DPI. In tissues incubated with 0.3 or 10 microM DPI for 30 min followed by washout for 60 min, the EC50 values for GTN-induced relaxation were increased 2-fold, and both GTN-induced cyclic GMP accumulation and vascular GTN biotransformation were decreased. This suggests an irreversible component to the inhibitory action of DPI. Together, these data provide evidence for the involvement of a flavoprotein (e.g., NADPH cytochrome P450 reductase) in the metabolic activation of GTN required for expression of its vasodilator activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965786

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Effect of overexpression of human aldehyde dehydrogenase 2 in LLC-PK1 cells on glyceryl trinitrate biotransformation and cGMP accumulation.

Authors:  Y D'Souza; Y Ji; B M Bennett
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

2.  Enantioselective inhibition of the biotransformation and pharmacological actions of isoidide dinitrate by diphenyleneiodonium sulphate.

Authors:  J D Ratz; J J McGuire; B M Bennett
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Changes in aldehyde dehydrogenase 2 expression in rat blood vessels during glyceryl trinitrate tolerance development and reversal.

Authors:  Y D'Souza; S Dowlatshahi; B M Bennett
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  A novel class of cytochrome P450 reductase redox cyclers: cationic manganoporphyrins.

Authors:  Brian J Day; Chirag Kariya
Journal:  Toxicol Sci       Date:  2005-02-09       Impact factor: 4.849

5.  Low dose nitrite enhances perfusion after fluid resuscitation from hemorrhagic shock.

Authors:  Pedro Cabrales
Journal:  Resuscitation       Date:  2009-10-04       Impact factor: 5.262

6.  Selective recapitulation of conserved and nonconserved regions of putative NOXA1 protein activation domain confers isoform-specific inhibition of Nox1 oxidase and attenuation of endothelial cell migration.

Authors:  Daniel J Ranayhossaini; Andres I Rodriguez; Sanghamitra Sahoo; Beibei B Chen; Rama K Mallampalli; Eric E Kelley; Gabor Csanyi; Mark T Gladwin; Guillermo Romero; Patrick J Pagano
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

7.  Aldehyde dehydrogenase-independent bioactivation of nitroglycerin in porcine and bovine blood vessels.

Authors:  Regina Neubauer; Gerald Wölkart; Marissa Opelt; Christine Schwarzenegger; Marielies Hofinger; Andrea Neubauer; Alexander Kollau; Kurt Schmidt; Astrid Schrammel; Bernd Mayer
Journal:  Biochem Pharmacol       Date:  2015-01-08       Impact factor: 5.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.